who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

DHR earnings date & Q2 2026 results · Danaher Corporation

US GAAP · $M · vs Q2 2025 · quarter ended 06/26/2026 · reported 07/21/2026

Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. · Wikipedia

More about the company

The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing.

Key growth driver: Revenue growth of +6% y/y — the report gives no segment split, so the driver is the whole business. · by the Q2 2026 report

When is DHR’s next earnings date?

Wednesday, October 21, 2026confirmed · before market open

Danaher Corporation (DHR) is scheduled to report results for the quarter ending Sep 2026 on Oct 21, 2026. Consensus EPS forecast: $1.96 (9 analysts), vs $1.89 in the same quarter last year.

What time does DHR report? Usually after market close: the last 4 results releases reached the SEC at 5:55 pm, 5:44 pm, 5:37 pm, 9:07 am ET.

Last report: Jul 21, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates and consensus: Nasdaq / Zacks Investment Research; companies do reschedule. Who else reports this week →

All figures in $M.

Revenue

$6,265

+5.5%

Gross profit

$3,611

+2.5%

57.6% margin (was 59.4%)

Operating income

$1,127

+48.3%

18.0% margin

Net income

$870

+56.8%

$1.23/sh · 13.9% margin

Sankey diagram of DHR (Danaher Corporation) earnings report for Q2 2026: revenue, costs and profitSales$6,265 · +5.5%Cost of Sales$2,654 · +10.0%Gross Profit$3,611 · +2.5%57.6% margin (was59.4%)SG&A$2,072 · −12.2%year ago incl. $432MimpairmentR&D$412 · +2.2%Operating Profit$1,127 · +48.3%18.0% marginNet Interest &Other Expense$49 · vs $105interest expense $107,income $61Pre-Tax Income$1,078 · +64.6%Income Tax$208 · +108%19.3% rateNet Earnings$870 · +56.8%$1.23/sh · 13.9% margin

Verdict: better than feared — sales +5.5% to $6.27B with core growth improving to +3.0% (+4.5% excluding respiratory testing) and Life Sciences posting its strongest quarter in years; the +57% jump in net earnings is mostly the base effect of last year's $432M trade-name impairment, while adjusted EPS grew a more honest 8% to $1.94.

Full-year 2026: core revenue growth 3.0–4.0%, adjusted diluted EPS raised to $8.45–8.60 (was $8.35–8.55) after the Masimo acquisition closed earlier than expected; Q3 core growth guided at 2.0–3.0%. Operating cash flow $1.5B, free cash flow $1.3B in the quarter.

Source and notation

Source: Danaher press release, 8-K EX-99.1 of 07/21/2026 (SEC EDGAR).

Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0

DHR earnings history: past report dates

Jul 20, 2026 Mon5:55 pmafter market closeJun 26, 2026$6.3B+6% y/y$1.23+60% y/y
Apr 20, 2026 Mon5:44 pmafter market closeMar 27, 2026$6.0B+4% y/y$1.45+10% y/y
Jan 12, 2026 Mon9:07 ambefore market openDec 31, 2025≈$6.8B+5% y/y≈$1.69+13% y/y
Oct 20, 2025 Mon5:39 pmafter market closeSep 26, 2025$6.1B+4% y/y$1.27+13% y/y
Jul 21, 2025 Mon5:47 pmafter market closeJun 27, 2025$5.9B+3% y/y$0.77−37% y/y
Apr 22, 2025 Tue6:08 ambefore market openMar 28, 2025$5.7B−1% y/y$1.32−9% y/y
Jan 13, 2025 Mon4:22 pmafter market closeDec 31, 2024≈$6.5B+2% y/y≈$1.50+3% y/y
Oct 21, 2024 Mon5:47 pmafter market closeSep 27, 2024$5.8B+3% y/y$1.12−26% y/y
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Danaher Corporation: 5-year financials

202524,5684,6903,6145,260878
202423,8754,8633,8995,296768
202323,8905,2024,7645,781821
202226,6437,5367,2097,401818
202124,8026,3776,4337,118742

$ millions, annual 10-K reports on SEC EDGAR (US GAAP).

How we calculate

Figures are the annual report lines as filed, no adjustments. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.

Corporate governance

2/2good

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

More
  • Feb 202610-K cover: a single registered class of common stock (Common stock, $0.01), NYSE. sec.gov ↗
  • Feb 2026Diluted share count −0.4% over 2020–2025; SBC of $298M = 1.2% of revenue; buybacks of $6.0B in 2024 and $3.1B in 2025 (XBRL). data.sec.gov ↗
  • Jan 2026The quarterly dividend was raised to $0.32 per share; dividend payments of $878M in 2025 versus $768M in 2024. sec.gov ↗
  • Aug 2025Class action Hawkins v. Danaher (2023) over bioprocessing revenue guidance: the court partly denied the motion to dismiss, the case is unresolved; the 10-K lists no other shareholder suits or SEC cases. sec.gov ↗

Scoring: 2.0 with no deductions = 2.0 (single share class, no dilution, dividends rising, Hawkins suit unresolved, no SEC cases)

Share classes
Single class of common stock (10-K cover: Common stock, NYSE).
Dilution
Diluted shares −0.4% over 2020–2025 (MCPS preferred conversion included), SBC 1.2% of revenue; buybacks of $6.0B (2024) and $3.1B (2025).
Disclosure
Full 10-K/10-Q reporting.
Dividends
Quarterly dividend rising, raised to $0.32 in 2025; no cuts.
Lawsuits & regulators
Class action Hawkins v. Danaher (D.D.C., 2023) over bioprocessing guidance partly survived the motion to dismiss (Aug. 2025), unresolved → no deduction; no SEC cases.
Related parties
The Rales brothers (directors, ~10%) receive a fixed $419K salary with no bonus; agreements for servicing their aircraft on a cost-reimbursement basis — immaterial.

How the score works · checked as of Sep 2026

Danaher Corporation (DHR) earnings: FAQ

When is DHR's next earnings date?

Danaher Corporation (DHR) is scheduled to report on Oct 21, 2026, before market open.

What time does DHR report earnings?

Danaher Corporation is scheduled to report before market open on Oct 21, 2026. Its last results releases were filed after market close, most recently at 5:55 pm ET on Jul 20, 2026.

When did DHR last report earnings?

Danaher Corporation reported Q2 2026 results on Jul 21, 2026.

What is the EPS estimate for DHR's next earnings?

The consensus EPS forecast is $1.96 (9 analysts), vs $1.89 in the same quarter last year.

Where can I find Danaher Corporation's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to DHR's filings; this page breaks the latest report down in a Sankey chart.

What was DHR's net income in Q2 2026?

Danaher Corporation reported net income of $870M for Q2 2026 (+56.8% year over year), under US GAAP.

Does Danaher Corporation pay dividends?

Yes. In 2025, Danaher Corporation paid $878M in dividends on its common stock, per its 10-K. Earlier years are in the five-year table above.

New to earnings reports? Start with how to read an earnings report.

How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report. Figures checked against the filing on 09/28/2026. How we make the breakdowns · Report an error

More reports: ELV · Q2 2026 · GILD · Q2 2026 · HCA · Q2 2026 · ISRG · Q2 2026 · JNJ · Q2 2026 · LLY · Q2 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q2 2026 · PFE · Q2 2026 · all reports

We use cookies the site needs to work and, with your consent, Google Analytics for visit statistics. Details are in our privacy policy.